INTRODUCTION
Chronic hepatitis C is one of the most common causes of chronic liver disease and is currently the leading indication for liver transplantation. Mutations in the hypervariable regions of the genome cause substantial viral heterogeneity during replication, leading to the persistence of the virus in infected patients and posing an obstacle to treatment and the development of an effective vaccine. The parenteral route, particularly injectable drug use, is the most common means of transmission. Symptoms of the disease (even fatigue and anorexia) are often mild or nonexistent. Chronic hepatitis C infection can lead to cirrhosis and hepatocellular carcinoma. Enzyme immunoassay is the screening test of choice for hepatitis C antibodies, and quantitative assays and genotyping may help predict response to treatment. Treatment options for hepatitis C have evolved greatly since the 1980s, and a combination of pegylated interferon and ribavirin is now becoming the standard treatment. The medications are not without side effects, and physicians need to consider such factors as age, general health, likelihood of response, and co-morbid illnesses before proceeding with treatment.
Virology
Post-transfusion hepatitis in the 1960s occurred in excess of 20% (1) . Efforts to discover the hepatitis C virus began after it was realized that most cases of posttransfusion hepatitis were not due to hepatitis A or B (2). In 1988, molecular cloning led to the discovery of hepatitis C virus as the cause of non-A, non-B hepatitis (3) .
There are six genotypes and 80 subtypes of HCV virus recognized, based on the nucleotide variability. T h e genotypes are designated by numbers, and the subtypes by lower case letters. Genotype 1 appears to be the most common genotype worldwide (40% to 80%) (4).
The HCV genome demonstrates substantial heterogeneity during viral replication because of mutations of two hypervariable regions within one of the envelope proteins. As a result, a population of closely related yet heterogeneous viruses called quasispecies exists in an infected individual. The immune system would ordinarily try to neutralize or prevent infection by producing specific antibodies against the HCV genome, but the mutating envelope proteins, which form the structural envelope of the virus, continue to escape recognition by preexisting antibodies. The generation of these mutants appears to be responsible for the persistence of HCV infection. It also poses a major obstacle to the design of an eff e c t i v e vaccine (5) .
Epidemiology
The estimated worldwide prevalence of HCV is 1%, but there is much geographical variation. In the United States some 3.9 million Americans are infected (6) . Hepatitis C represents a major economic burden. Current estimates of medical and work-loss costs of HCV-related acute and chronic liver disease are over $600 million annually in the United States alone (CDC, unpublished data). Wong and colleagues project an estimated 165,900 deaths from chronic liver disease, 27,200 deaths from hepatocellular carcinoma, and $10.7 billion in direct medical expenditures for HCV in the United States alone from the year 2010 through 2019 (7) .
Hepatitis C is present in blood and therefore is most easily transmitted by parenteral routes. The relative importance of risk factors for the transmission of hepatitis C virus has changed in the past decade. Blood products were the single most important risk factor for HCV transmission during the 1980s, when an estimated 230,000 de novo infections occurred annually in the United States (CDC, unpublished data). However, the annual number of new infections has declined by >80% to 36,000 by 1996 (8) as a result of blood product screening and the use of erythropoietin (9) . Since 1994, the estimated risk of HCV infection via transfusion is 0.01% to 0.001% per unit transfused (10) . C u r r e n t l y, injectable drug users have the highest prevalence of HCV infection (11) . One study showed the seroprevalence to be 76.9% among users reporting up to six years of injection (11) . HCV infection also has been associated with intranasal cocaine use (12), although it is unclear whether this represents an independent mode of transmission or a surrogate for drug injection.
The risk of sexual transmission of HCV appears to be neglible (13) . Studies involving long-term spouses of patients with chronic HCV infection who had no other risk factors for infection indicate that the average prevalence of HCV infection was low at 1.5% (range: 0% to 4.4%) (14) . In studies from other countries, the average anti-HCV prevalence among nonsexual household contacts was higher at 4% (15) . However, most of these studies were done in countries where exposures from contaminated equipment used in traditional and nontraditional medical procedures may have contributed to clustering of HCV infections in families (16) ( Fig. 1 ).
CLINICAL MANIFESTATIONS

Hepatic manifestations
Most patients with acute HCV infection are asymptomatic. Clinical jaundice occurs in less than one third of newly infected patients (17) . Symptoms such as anorexia, weight loss, or fatigue are typically mild and do not interfere with daily routine (18) . Patients with chronic hepatitis C are also usually asymptomatic. When symptoms occur, fatigue is a common complaint, followed by abdominal pain, anorexia, and weight loss. The degree of fatigue is unrelated to the severity of the liver disease. Jaundice is rare in chronic disease until hepatic decompensation develops. There are no specific signs or symptoms for acute hepatitis C infection. In advanced stages, ascites, encephalopathy, and gastrointestinal bleeding may occur as portal hypertension develops. Symptoms and laboratory tests are of little value in making the diagnosis of cirrhosis (19) .
Extrahepatic manifestations
Extrahepatic manifestations, including mixed cryoglobulinemia, porphyria cutanea tarda and membranoproliferative glomerulonephritis, are considered to be of immunologic origin. Other extrahepatic conditions include leukocytoclastic vasculitis, focal lymphocytic sialadenitis, and idiopathic pulmonary fibrosis. Some studies have demonstrated an association between HCV infection and B-cell non-Hodgkin's lymphoma (20) .
Increased expression of autoantibodies and increased prevalence of autoimmune disorders are also associated with HCV infection, thyroid disorders being the most common. Antithyroid antibodies are present in 5.2% to 12.5% of patients and hypothyroidism 3.1% to 5.5%. Chronic lymphocytic sialadenitis is also another autoimmune disease described in patients with chronic hepatitis C (21) .
Natural history
The incubation period of acute HCV infection is about seven weeks (22) . Only 15% of cases of acute HCV resolve spontaneously; infection persists in a vast majority (>80%) of patients. Progression of the disease is largely silent, as infection of the virus is often identified only on routine biochemical screening or during the course of blood donation. In some 20 to 30% of patients with chronic H C V, cirrhosis will develop after 20 to 30 years (23). Factors identified as potential promoters for disease progression can be divided into viral related, host related, or extraneous influences (Tab. I). Hepatocellular carcinoma (HCC) develops in about 15% of those who develop cirrhosis. The annual risk of primary HCC in HCVrelated cirrhosis is estimated to be 1% to 4%. The time to the development of HCC from the time of HCV acquisition ranges from 10 to 50 years (24) .
Serologic/viral tests
The diagnosis of HCV infection depends on the detection of antibodies to the virus. Unlike hepatitis A and B, antibodies to HCV are non-neutralizing. Currently, the third generation of enzyme immunoassay (EIA) is used for screening purposes. Its sensitivity is over >99% in immunocompetent individuals. False-negative test results have been reported in immunocompromised hosts, including organ transplant recipients, hemodialysis patients, and patients with HIV (25) .
A positive EIA generally requires confirmation by either a recombinant immunoblot assay (RIBA) or direct viral measurement. Assays for direct viral measurement include polymerase chain reaction (PCR) and branched DNA amplification (bDNA). A positive RIBA result confirms exposure to HCV, but cannot distinguish between active infection and previous exposure. A negative RIBA essentially rules out previous or current HCV infection in most patients. However, in immunocompromised patients, direct viral measurement may be needed to confirm HCV infection. In acute hepatitis, the HCV RIBA may also be negative in the early stages.
Direct viral measurement confirms the diagnosis of HCV and may also reveal if there is viral replication. Both qualitative and quantitative PCR assays (which amplify reverse-transcribed complementary DNA) are available. Qualitative assays are more sensitive and detect viral genome as low as 100 copies/mL (26) . Quantitative assays, by comparison, have lower limits of detection of 500 viral genome copies/mL (27) . However, quantitative testing, by making the level of HCV RNA available, may help predict response to therapy. Both PCR and bDNA measurements are highly sensitive and specific, but their high costs limit their role as screening tests. Compared with PCR, the bDNA quantitation assay test is less sensitive (26) .
Direct viral measurements and genotype assays are routinely done before initiating treatment for hepatitis C.
The genotype may help predict sustained virological response (see Therapy).
Therapy
The treatment options have evolved rapidly in the past years, the goal being to eliminate the virus and prevent progression to cirrhosis. Interferons, which are natural glycoproteins, are the mainstay of antiviral therapy against HCV (28) . Several studies confirmed that low doses of alpha interferon improved liver tests and histology in patients with chronic hepatitis C (29) . The results of a meta-analysis demonstrated that treatment with 12 months or longer of interferon increased sustained response from 14% to 35% (30) .
Ribavirin, a guanosine nucleoside analogue that inhibits the in vitro replication of DNA and RNA viruses, has also been studied. As monotherapy, it had no significant effect on HCV levels in humans (31) . However, combination of interferon and ribavirin demonstrated a sustained virologic response rate of 41% in two large, multicenter studies (32, 33) .
The covalent attachment of a polyethylene glycol (PEG) moiety to interferon has resulted in a slower clearance and longer half-life. Pegylation allows once-weekly administration, compared to the three-times-a-week injection of the non-pegylated form of interferon. One trial demonstrated a 30% sustained response with pegylated interferon alfa-2a compared with 8% with interferon alfa-2a (34) . In another study, a higher sustained virologic response was achieved with peginterferon alfa-2a than interferon alfa-2a (39 percent vs. 19 percent, P=0.001) (35) . T h e combination of pegylated interferon alfa-2a with ribavirin, therefore, is rapidly gaining favor as the initial treatment of choice. The sustained virological response was 34-42% for genotype 1, and 80-88% for genotypes 2 and 3 (36) .
Interferon has as its most common side effects flu-like symptoms, fatigue, myalgia, and arthralgia. It may also cause or exacerbate depression. Thyroiditis and bone marrow suppression (especially leukopenia and thrombocytopenia) are also commonly seen. Other side effects include nausea, diarrhea, alopecia and reactions at the site of injection. The most common adverse effect of ribavirin is dose-dependent and reversible intravascular hemolytic anemia. In most patients, the hemoglobin decreases by 2 to 3 g/dL in the first four to eight weeks of therapy (31) , and it resolves within four to eight weeks of completing therapy. The dose of ribavirin may need to be reduced because of anemia. Ribavirin can also cause cough, rash, insomnia and anorexia, and it is also teratogenic. Because of the risk of teratogenicity, patients and their partners need to use contraception. In deciding to treat patients with chronic hepatitis C, the physician needs to consider the age, general health, likelihood of response, and comorbid illnesses of each patient. The National Institute of Health and European Consensus Development Conferences both suggest that patients with elevated aminotransferase levels, detectable serum HCV RNA, and portal fibrosis or moderate inflammation on liver biopsy should be evaluated for therapy (37, 38) . Patients with decompensated liver disease, active alcohol or drug use, major depression, autoimmune disease, serious comorbid illnesses, and pregnancy are poor candidates for therapy.
Liver biopsy is usually done before therapy in order to determine the extent of liver damage. The result of the biopsy may help predict the rate of disease progression and estimate prognosis. The presence of some degree of portal fibrosis generally means more aggressive disease and favors treatment. Liver biopsy may therefore assist in deciding whether to initiate or defer therapy. This is particularly true in patients less likely to respond to antiviral treatment, such as those infected with genotype 1.
Several variables may predict a more favorable response to therapy: HCV genotype 2 or 3, low pretreatment HCV RNA levels, mild chronic hepatitis, absence of portal fibrosis or cirrhosis, female gender, and age younger than 40 years (39) .
CONCLUSION
Chronic hepatitis C has emerged as a major public health problem especially as more patients with chronic hepatitis C become older and develop end stage liver disease requiring liver transplantation. Developing an e ffective vaccine may continue to pose a challenge because of the heterogeneity of the virus. Preventing hepatitis C infection by strategies based on known risk factors is therefore important. New treatment options have already improved the rate of viral clearance from infected patients, but more efforts are needed to achieve not only higher rates of response but also longer durations of such responses.
